Alpha Teknova, Inc.
TKNO Nasdaq In Vitro & In Vivo Diagnostic Substances Financials FY2020βFY2025
Last close Β· Oct 23, 2026
$6.42
4.4%What Alpha Teknova, Inc. does
No business description yet.
- Legal name
- Alpha Teknova, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 2, 2026
- Accession Β· CIK
- 0001850902-26-000002
0001850902
Revenue and margins
Alpha Teknova, Inc. had $40.5M of revenue in fiscal 2025, up 7.4% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$9.8M in fiscal 2025, β24.2% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Alpha Teknova, Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 14.4%.
Balance sheet
Cash, debt and the ratios that show how comfortably Alpha Teknova, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $87.5M | $42.2M | $28.5M | $30.4M | $21.3M |
| Debt incl. finance leases | $11.9M | $22.0M | $13.3M | $9.4M | $13.1M |
| Debt / equity | 0.1x | 0.2x | 0.1x | 0.1x | 0.2x |
| Current ratio | 13.1x | 5.6x | 5.1x | 3.8x | 4.6x |
| Quick ratio | 12.4x | 4.5x | 3.8x | 3.2x | 3.6x |
| Total assets | $167M | $152M | $129M | $119M | $104M |
| Total liabilities | $23.3M | $52.4M | $38.6M | $36.4M | $34.8M |
| Shareholders' equity | $143M | $99.9M | $90.0M | $82.4M | $68.8M |
| Net debt (β = net cash) | β$75.6M | β$20.3M | β$15.2M | β$21.0M | β$8.2M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 9 | 2 / 9 | 4 / 9 | 4 / 9 | 5 / 9 |
| Accruals ratio | 1.7% | β0.6% | β12.6% | β12.8% | β11.6% | β7.7% |
| Altman Z'' | 3.59 | 9.50 | 0.80 | 0.14 | β0.61 | β1.59 |
6 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $31.3M | $36.9M | $41.4M | $36.7M | $37.7M | $40.5M |
| Net interest income | $0.1M | β$0.6M | $0.2M | β$0.8M | β$0.7M | β$0.7M |
| Gross profit | $17.8M | $17.6M | $17.5M | $10.3M | $7.2M | $13.4M |
| Research and development | $1.5M | $4.3M | $7.7M | $5.6M | $2.8M | $2.2M |
| Operating income | $4.7M | β$12.0M | β$49.7M | β$35.6M | β$26.1M | β$17.0M |
| Pretax income | $4.7M | β$12.6M | β$49.4M | β$37.1M | β$26.8M | β$17.2M |
| Income tax | $1.2M | β$2.8M | β$1.9M | β$0.3M | β$0.1M | $0.1M |
| Net income | $3.6M | β$9.8M | β$47.5M | β$36.8M | β$26.7M | β$17.3M |
| Net income to common | $0.6M | β$9.8M | β | β | β | β |
| Diluted EPS | $0.16 | β$0.61 | β$1.69 | β$1.16 | β$0.57 | β$0.32 |
| Diluted shares | 0.00B | 0.02B | 0.03B | 0.03B | 0.05B | 0.05B |
| Cash flow | ||||||
| Cash from operations | $2.5M | β$9.1M | β$27.4M | β$18.8M | β$12.4M | β$8.6M |
| Capital expenditure | $5.5M | $19.9M | $28.1M | $7.9M | $1.1M | $1.1M |
| Free cash flow | β$3.0M | β$28.9M | β$55.5M | β$26.7M | β$13.5M | β$9.8M |
| Depreciation and amortization | $2.0M | $2.9M | $3.2M | $5.7M | $6.6M | $6.3M |
| Stock-based compensation | $0.3M | $1.6M | $3.7M | $4.1M | $3.7M | $3.4M |
| Balance sheet | ||||||
| Cash and short-term investments | $5.1M | $87.5M | $42.2M | $28.5M | $30.4M | $21.3M |
| Total debt | $0.0M | $11.9M | $22.0M | $13.3M | $9.4M | $13.1M |
| Current assets | $16.4M | $101M | $61.1M | $45.7M | $42.8M | $34.5M |
| Current liabilities | $4.0M | $7.7M | $10.9M | $8.9M | $11.2M | $7.5M |
| Inventory | $3.6M | $5.4M | $12.2M | $11.6M | $6.8M | $7.1M |
| Property and equipment, net | $10.0M | $29.8M | $51.6M | $50.4M | $45.8M | $41.7M |
| Goodwill | $16.6M | $16.6M | $0.0M | β | β | β |
| Intangible assets | $19.9M | $18.7M | $17.6M | $14.2M | $13.1M | $11.9M |
| Total assets | $62.9M | $167M | $152M | $129M | $119M | $104M |
| Total liabilities | $10.5M | $23.3M | $52.4M | $38.6M | $36.4M | $34.8M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $16.8M | $143M | $99.9M | $90.0M | $82.4M | $68.8M |
| Margins | ||||||
| Gross margin | 56.7% | 47.8% | 42.2% | 28.1% | 19.2% | 33.2% |
| Operating margin | 14.9% | β32.5% | β119.9% | β96.9% | β69.3% | β41.9% |
| EBITDA margin | 21.4% | β24.7% | β112.3% | β81.5% | β51.8% | β26.2% |
| Net margin | 11.4% | β26.6% | β114.6% | β100.3% | β70.9% | β42.6% |
| FCF margin | β9.5% | β78.5% | β134.1% | β72.9% | β35.8% | β24.2% |
| Net interest share of revenue | 0.3% | β1.6% | 0.5% | β2.3% | β1.8% | β1.8% |
| Returns | ||||||
| Return on capital | 30.3% | β14.0% | β49.3% | β37.6% | β33.6% | β22.1% |
| Return on capital employed | 7.9% | β7.6% | β35.1% | β29.7% | β24.3% | β17.7% |
| Return on equity | 21.3% | β12.3% | β39.1% | β38.7% | β31.0% | β22.8% |
| Return on assets | 5.7% | β8.5% | β29.8% | β26.2% | β21.6% | β15.5% |
| Return on tangible equity | β | β9.1% | β57.7% | β48.5% | β38.6% | β30.4% |
| Growth | ||||||
| Revenue growth | β | 17.9% | 12.3% | β11.4% | 2.9% | 7.4% |
| Net income growth | β | β374.6% | β | β | β | β |
| EPS growth | β | β481.3% | β | β | β | β |
| Share count change | β | 323.3% | 74.6% | 13.3% | 46.9% | 14.4% |
| Financial health | ||||||
| Net debt / EBITDA | β0.8x | β | β | β | β | β |
| Debt / equity | 0.0x | 0.1x | 0.2x | 0.1x | 0.1x | 0.2x |
| Current ratio | 4.1x | 13.1x | 5.6x | 5.1x | 3.8x | 4.6x |
| Quick ratio | 3.2x | 12.4x | 4.5x | 3.8x | 3.2x | 3.6x |
| Capital allocation | ||||||
| Capex / revenue | 17.5% | 53.9% | 68.0% | 21.6% | 3.0% | 2.8% |
| Stock comp / revenue | 1.0% | 4.2% | 9.0% | 11.3% | 9.7% | 8.5% |
| Quality scores | ||||||
| Piotroski F-score | β | 2.0 | 2.0 | 4.0 | 4.0 | 5.0 |
| Altman Z'' | 3.6 | 9.5 | 0.8 | 0.1 | β0.6 | β1.6 |
| Accruals ratio | 1.7% | β0.6% | β12.6% | β12.8% | β11.6% | β7.7% |
Source: SEC EDGAR XBRL filings (CIK 0001850902). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.